Back to Catalog
Sidewinder Therapeutics
sidewindertherapeutics
Bispecific ADC oncology company targeting solid tumors with $162M raised.
Total Funding
$162M
sector:biotech
stage:series_b
oncology
ADC
antibody-drug-conjugate
bispecific
bladder-cancer
lung-cancer
colorectal-cancer
solid-tumors
preclinical
OrbiMed
Frazier
Novartis
Lonza-Synaffix
Full Profile Gated
Register as a Qualified Purchaser to access the full profile of Sidewinder Therapeutics, including financial analysis, competitive landscape, and investment thesis.